0000000000621499

AUTHOR

Senna G.

showing 2 related works from this author

Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma.

2021

Objective: This study analysed whether the persistence of both reversible airway obstruction (RAO) and elevated BE counts was associated to reduced asthma control and accelerated lung function decline in treated severe asthmatics. Methods: About 202 severe asthmatics were studied after 12–120 months of step-5 treatment associated to anti-IgE therapy. Following treatments, reversibility tests, after inhaling 400 mcg of Salbutamol, were performed. FEV1 > 12% or ≤12% changes differentiated RAO+ from RAO− subjects. Blood eosinophil (BE) counts after treatment were considered. Results: Pre-/post-treatment bronchodilator FEV1% and ACT were lower (61% [50–71], 74.4% [62.5–83.7] and 20[18–22]), …

Pulmonary and Respiratory Medicinesevere asthmamedicine.medical_specialtymedicine.drug_classSevere asthmaEosinophilSettore MED/10 - Malattie Dell'Apparato RespiratorioGastroenterologyPersistence (computer science)03 medical and health sciences0302 clinical medicineInternal medicineBronchodilatorallergic asthma blood eosinophil bronchodilator reversibility lung function decline severe asthma salbutamolForced Expiratory VolumemedicineSettore MED/10Immunology and AllergyHumans030212 general & internal medicineBlood eosinophilLungGenetics (clinical)Lung functionBronchodilator Agentallergic asthma; blood eosinophil; bronchodilator reversibility; lung function decline; severe asthma; salbutamol; bronchodilator agents; eosinophils; forced expiratory volume; humans; lung; airway obstruction; asthmabusiness.industrylung function declineAirway obstructionmedicine.diseaseAsthmaBronchodilator AgentsAirway ObstructionEosinophilsbronchodilator reversibility030228 respiratory systemsalbutamolSalbutamolBlood eosinophilsbusinessallergic asthmamedicine.drugHumanblood eosinophilThe clinical respiratory journalREFERENCES
researchProduct

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overvi…

2021

To date, four vaccines have been authorised for emergency use and under conditional approval by the European Medicines Agency to prevent COVID-19: Comirnaty, COVID-19 Vaccine Janssen, Spikevax (previously COVID-19 Vaccine Moderna) and Vaxzevria (previously COVID-19 Vaccine AstraZeneca). Although the benefit–risk profile of these vaccines was proven to be largely favourable in the general population, evidence in special cohorts initially excluded from the pivotal trials, such as pregnant and breastfeeding women, children/adolescents, immunocompromised people and persons with a history of allergy or previous SARS-CoV-2 infection, is still limited. In this narrative review, we critically overv…

AllergyIMPACTCOVID-19 VaccineBreastfeedingReview ArticleToxicologySettore MED/42 - Igiene Generale E ApplicataCLINICAL CHARACTERISTICSPregnancyPharmacology (medical)Pregnancy Complications InfectiousChildOUTCOMESeducation.field_of_studyCANCERVaccinationEuropeCORONAVIRUS DISEASE 2019 CLINICAL CHARACTERISTICS CANCER RECIPIENTS SEVERITY OUTCOMES IMPACT RATESBreast FeedingChild PreschoolPractice Guidelines as TopicFemale2019-nCoV Vaccine mRNA-1273HumanAdultmedicine.medical_specialtyCOVID-19 Vaccines2019-nCoV Vaccine mRNA-1273; Adolescent; Adult; BNT162 Vaccine; Breast Feeding; COVID-19; COVID-19 Vaccines; ChAdOx1 nCoV-19; Child; Child Preschool; Europe; Female; Humans; Infant; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications Infectious; SARS-CoV-2; Hypersensitivity; Immunocompromised HostAdolescentSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PopulationMEDLINECORONAVIRUS DISEASE 2019Immunocompromised HostChAdOx1 nCoV-19medicineHypersensitivityHumansRATESeducationBNT162 VaccinePharmacologyPregnancybusiness.industrySARS-CoV-2COVID-19Infantmedicine.diseaseVaccine efficacyRECIPIENTSSEVERITYFamily medicinePregnancy Complications Infectioubusiness
researchProduct